News & Research
In the News
CoQ10 is one of the most important, potent antioxidants found naturally in the body to power each and every cell, as well as provide protection against free radical damage.† High levels of CoQ10 are especially essential in your high-activity cells, such as heart muscle cells, brain cells, and neurological system cells.
And we're not the only ones singing the praises of CoQ10! This powerhouse is making headlines across the country for its noticeable effects on heart health and neurological function.†
The CoQ10 of Choice for Researchers.
As
THE product used in the National Institutes of Health (NIH)-funded clinical trials, Vitaline CoQ10 is the only CoQ10 product independently proven to be absorbed, proven safe at high doses, spike serum levels of CoQ10, cross the cell wall, spike mitochondrial levels of CoQ10, cross the blood-brain barrier and improve overall health.
†1
Our CoQ10 has been the subject of more than 25 published clinical trials and presentations. Additionally, new research is now underway for cardiovascular, neurological and brain supportive benefits.
† At Vitaline, we are committed to supporting scientific advancement and clinical research that demonstrates the effectiveness of our products.
Vitaline was asked to provide coenzyme Q10 by researchers looking for a product from a reputable company. Vitaline has no influence, affiliation, sponsorship, or financial support (other than the provision of our products) with these institutions.
1 Matthews RT, Yang L, Brown S, Baik MF. Coenzyme Q10 administration increases brain mitochondrial concentration and exerts neuroprotective effects. Proc Natl Acad Sci USA. 1998;95:8892-8897.
Published Clinical Studies
Vitaline CoQ10 has been the subject of many independent, peer-reviewed published clinical trials offering proof of safety, efficacy and tolerability.
†
Of note, Vitaline CoQ10 has been the focus of cutting edge research showing demonstrated benefits for neurological health.
†1-17
Vitaline has also been clinically proven to support heart and cardiovascular health.
†18-20
1 Shults CW, Oakes D, Kieburtz K, et al. Effects of Coenzyme Q10 in Early Parkinson's Disease. Arch Neurol. 2002:59:1541-1550.
2 The Huntington Study Group. A Randomized, Placebo-Controlled Trial of Coenzyme Q10 and Remacemide in Huntington's Disease. Neurology. 2001:57:397-404.
3 Schilling G, Coonfield ML, Ross CA, Borchelt DR. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett. 2001 Nov 27;315(3):149-53.
4 Fallon J, Matthews RT, Hyman BT, Beal MF. MPP+ produces progressive neuronal degeneration which is mediated by oxidative stress. Exp Neurol. 1997 Mar;144(1):193-8.
5 Feigin A, Kieburtz K, Como P, Hickey C, Claude K, Abwender D, Zimmerman C, Steinberg K, Shoulson I. Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord. 1996;11(3):321-323.
6 Flint Beal M, Matthews RT. Coenzyme Q10 in the central nervous system and its potential usefulness in the treatment of neurodegenerative diseases. Mol Aspects Med. 1997;18(S);s169-s179.
7 Flint Beal M, Henshaw DR, Jenkins BG, Rosen BR, Schulz JB. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol. 1994;36:882-888.
8 Jenkins BG, Brouillet E, Chen YC, Storey E, Schulz JB, Kirschner P, Beal MF, Rosen BR. Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J Cereb Blood Flow Metab. 1996 May;16(3):450-61.
9 Matthews Rt, Yang L, Browne S, Baik M, Flint Beal M. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci. 1998;95:8892-8897.
10 Schulz B, Matthews RT, Henshaw DR, Beal MF. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience. 1996;71(4):1043-1048.
11 Shults CW, Flint Beal M, Fontaine D, Nakano K, Haas RH. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology. 1998;50:793-795.
12 Shults CW, Haas RH, Passov D, Beal MF. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol. 1997 Aug;42(2):261-4.
13 Schulz JB, Henshaw R, Matthews RT, Flint Beal M. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp Neurol. 1995;132:279-283.
14 Koroshetz WJ, Jenkins BG, Rosen BR, Flint Beal M. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol. 1997;41:160-165.
15 Ferrante KL, Shefner J, Zhang H, et al. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology. 2005 Dec 13;65(11):1834-1836.
16 Shults CW, Flint Beal M, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol. 2004 Aug;188(2):491-4.
17 Flint Beal M, Matthews RT, Tieleman A, Shults CW. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 1998;783:109-114.
18 Langsjoen P, Langsjoen A, Willis R, and Folkers K. The Aging Heart: Reversal of Diastolic Dysfunction Through the Use of Oral CoQ10 in the Elderly. Anti-Aging Medical Therapeutics. Klatz RM and Goldman R (eds.). Health Quest Publications. 1997;113-120.
19 Langsjoen PH, Langsjoen A, Willis R, Folkers K. Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Mol Aspects Med. 1997;18(S):s145-s151.
20 Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol. 2004 Nov 15;94(10):1306-10.
Related Links
- National Parkinson Foundation: The Mission of the National Parkinson Foundation is to find the cause of and the cure for Parkinson disease through research, to improve the quality of life for persons with Parkinson and their caregivers, and to educate persons with Parkinson, their caregivers, healthcare professionals, and the general public about Parkinson disease and its treatment.
- Parkinson Study Group: The Parkinson Study Group (PSG) is a non-profit, cooperative group of Parkinson's disease experts from medical centers in the United States and Canada who are dedicated to improving treatment for persons affected by Parkinson's disease.
- Parkinson Research Foundation: This national website is dedicated to Parkinson's disease and is the ultimate resource for information on Parkinson's Research.
- Huntington's Disease Society of America: HDSA is committed to promoting and supporting research to find a cure for Huntington's Disease, helping families and communities affected by this disease and educating the public and healthcare professionals about HD.
- Huntington's Study Group: Read more about the largest clinical study ever of a potential treatment for Huntington's disease.